



SURVIVORSHIP: KEY CONSIDERATIONS WHEN BUILDING A BREAST CANCER PROGRAM

JOANNE MORTIMER, MD, FACP, FASCO

Director, Women's Cancers Program Vice Chair, Medical Oncology Professor, Division of Medical Oncology & Experimental Therapeutics Associate Director for Education and Training Baum Family Professor of Women's Cancers City of Hope National Medical Center





Consultant for AstraZeneca, GlaxoSmithKline, Incyte, Mesoblast, Novartis, Pfizer, and Puma Biotechnology.





Breast Cancer Survivors – The challenges

- After completion of active therapy, patients often feel abandoned
- Breast cancer survivors are the largest population of cancer survivors

 \circ Even if cured, are at high risk





Reasons to have physicians follow survivors

 Longstanding relationship and understanding of the individual's disease

 Helps us understand longterm complications of therapy

Make us "feel good"





Reasons to transition patients to other caregivers

- Opens up space in crowded clinics
- Ability to see newly diagnosed patients sooner
- Provides a focused clinic for care and research
- Allows for more general medical attention



Commission on Cancer focus on Survivorship

- Created mandates for the use of Treatment Summaries and Survivorship Care Plans
 - Started with 15%
 - \circ Increased to 50%



City of Hope Center for Cancer Survivorship										
Hope Treatment Summary										
1500 East Duarte Road, Duarte,	CA 91010		PATIEN		OPM	TIC	NN I			
Name:		D	OB:		MRN	_		Race/	Ethnicity: Cauc	asian, Non-Hispanic
Address: Phone:										
CLINICAL INFORMATION										
Diagnosis 1: Right Breas	t Cancer, Infi	ltratin	g ductal carci	noma v	with m	inor	DCIS			
Date of Diagnosis: 9/1/2008 Age at Diagnosis: 58 years Definitive Surgery Date: 10/10/2008										
Pathologic Stage: IIIA, T	3, pN2a, M0						(Oncotyp	e DX score: N	/A
ER Status: Negative			PR Status:	Vegati	ve		- 1		HER2 Status: P	ositive
Comorbid Conditions: S	kin cancer in	1996								
Family History: None/R	ernote family	histor	У						Genetic	Test: N/A
Echocardiogram or MUG	A result prio	or to c	hemotherapy	: EF =	= 6	9	%	10/	23/2008	
			TREAT	MENT	r info	RM	ATION			
SURGERY			Dete		6				La disatan	C
Procedure Ultrasound guided biopsy	of right brees	+	Date		Surge	2011			Institution	Comments
and right lymph node	or right breas	sc.	9/30/2008	3	Caro	IW٥	ong, MD		City of Hope	
Right Axillary Node Dissec	tion:		10/10/200	8	Laura	a Kru	iper, MD		City of Hope	13 nodes removed/ 5 nodes
Right Mastectomy 10/			10/10/200	10/10/2008 Laura Kruper, MD				City of Hope positive		
Breast Reconstruction: DI	P flap		6/22/2010		Shar	on C	lancy, Ml	D	City of Hope	
CHEMOTHERAPY REGIMEN S										
Regimen/Protocol: Adju										
Date Initiated: 10/23/20	08		Date Comple	ted: 2/	-				On-Study: No	
Treating Institution: City	-				Hea	_			Joanne Mortime	er, MD
CHEMOTHERAPY & BIOLOG									uvant? No	-4
Drug Name	Route	Cum	ulative Dose	Units			f cycles g	given	% dose reduct	tion
Doxorubicin	IV		240	mg∕r		4			0	
Cyclophosphamide	IV		2400	mg/r		4			0	
Paclitaxel	IV		175	mg∕ r		1			N/A	
Abraxane	IN.		514	mg/r		2			N/A	
	tart Date /20/2009		Date /30/2009	Pre-t	herap 69	y eje	ection fra	action /2008	Most recent 62	ejection fraction 4/7/2009
RADIATION	, 20, 2009	9/	30/2009		09		10/ 23/	2000	02	4/7/2009
Site/Field		S	tart Date	tart Date Sto		p Date F		tions	Total Dose	Units
Right supraclavicular		4/	/15/2009	5/2	2/200)9	2	8	50.4	Gy
Right chest wall		4/	/15/2009	5/2	2/200			8	50.4	Gy
Right chest wall boost		5/	/26/2009	6/1	1/200	9	5	5	10	Gy
Radiation Oncologist: Na	ayana Vora, I	ИD					Institut	ion: Cit	y of Hope	



City of Hope Center for Cancer Survivorship Treatment Summary

1500 East Duarte Road, Duarte, CA 91010

FOLLOW-UP AND SURVIVORSHIP CARE					
Follow-up care	When/How Often?	Coordinating Provider			
Breast survivorship clinic visits	Yearly	Helene Zonder, NP			
Primary oncologist visits	Recommendation to be made by oncologist	Joanne Mortimer, MD			
Primary Care Visits	As needed for routine screening, disease prevention, and management of co-morbidities	Primary Care Provider			

Potential late effects of treatment: See Survivorship Care Plan

ONCOLOGY TEAM MEMBER CONTACTS	SURVIVORSHIP CARE PROVIDER CONTACTS
Oncologist	Provider
Name: Joanne Mortimer, MD	Name: Helene Zonder, Nurse Practitioner
Contact Info: 626-256-4673 ext 69200	Contact Info: 626- 471-7341
RN	Clinical Research Assistant
Name: Sandra Helton	Name: Meghan Zomorodi
Contact Info: 626-256-4673 ext 69200	Contact Info: 626- 471-7341
OTHER CA	RE TEAM MEMBER CONTACTS
Title	Title
Name:	Name:
Contact Info:	Contact Info:
Title	Title
Name:	Name:
Contact Info:	Contact Info:
Contact Info:	Contact Info:
Contact Info: Specific Health Care Recommendations Provided	
Specific Health Care Recommendations Provided	
SPECIFIC HEALTH CARE RECOMMENDATIONS PROVIDED Prevention and Wellness	© Dietician
Specific Health Care Recommendations Provided Prevention and Wellness National Cancer Institute: Facing Forward National Institute of Health:	REFERRALS PROVIDED:
Specific Health Care Recommendations Provided Prevention and Wellness National Cancer Institute: Facing Forward	© Dietician
Specific Health Care Recommendations Provided Prevention and Wellness National Cancer Institute: Facing Forward National Institute of Health: What Breast Cancer Survivors Need to Know about Osteoporosis Menopausal Symptoms and CAM	© Dietician © Physical therapist
SPECIFIC HEALTH CARE RECOMMENDATIONS PROVIDED Prevention and Wellness National Cancer Institute: Facing Forward National Institute of Health: What Breast Cancer Survivors Need to Know about Osteoporosis Menopausal Symptoms and CAM City of Hope: Eat Your Way to a Healthier Heart	© Dietician © Physical therapist © Psychologist
SPECIFIC HEALTH CARE RECOMMENDATIONS PROVIDED Prevention and Wellness National Cancer Institute: Facing Forward National Institute of Health: What Breast Cancer Survivors Need to Know about Osteoporosis Menopausal Symptoms and CAM City of Hope: Eat Your Way to a Healthier Heart Vaccinations for Adults U.S. Department of Health:	REFERALS PROVIDED: Distician Physical therapist Psychologist Social worker
SPECIFIC HEALTH CARE RECOMMENDATIONS PROVIDED Prevention and Wellness National Cancer Institute: Facing Forward National Institute of Health: What Breast Cancer Survivors Need to Know about Osteoporosis Menopausal Symptoms and CAM City of Hope: Eat Your Way to a Healthier Heart Vaccinations for Adults	REFERALS PROVIDED: Distician Physical therapist Psychologist Social worker Smoking cessation counselor

SURVIVORSHIP CARE PLAN

POTENTIAL LATE SIDE EFFECTS	RECOMMENDATIONS	LINKS
Potential for Recurrence of Breast Cancer	 Your medical oncologist will discuss the timing and frequency of your mammograms. Perform a breast self-exam every month. This is not a substitute for a mammogram. You should have a history and physical examination every 3-6 months for the first 3 years after treatment, then every 6-12 months for the next 2 years and then annually. Report any new lumps, bone pain, chest pain, shortness of breath, abdominal pain, or persistent headaches. 	American Cancer Society: Living with Uncertainty: The Fear of Cancer Recurrence <u>http://www.cancer.org/docr</u> <u>oot/MLT/content/MLT_4_1</u> <u>x_Living_With_Uncertainty</u>
Potential for Fatigue	 Fatigue is one of the most common complaints of people diagnosed with cancer and cancer survivors. Although fatigue is frequently an expected, temporary side effect of treatment, other factors my cause it to continue. Fatigue is complex, and has biological, psychological and behavioral causes. It is often expressed in different ways, such as feeling tired, weak, exhausted, weary, wornout, heavy or slow. You may find that you tire more quickly when doing routine tasks or lack the energy for the activities you used to enjoy. Discuss with your health care provider if you are experiencing fatigue, and ask for information about fatigue related to underlying causes such as sleep disorders and inactivity, anxiety, depression, social and financial stressors, medications, eating habits and side effects of other health conditions. Pay attention to your sleep habits; sleep at least 7-9 hours per night. Maintain a comfortable balance between activity and rest Exercise most days of the week Eat a healthy diet. 	Cancer National Institute- Fatigue <u>http://www.cancer.gov/canc</u> <u>ertopics/pdq/supportivecare/</u> <u>fatigue/patient</u>
Potential for Problems with Employers, Insurability, and Continuity of Care	 Maintain your health insurance Review your employer's health benefits concerning major illness. Share your treatment summary with all members of your health care team Know your insurance and/or MediCare coverage Review medicolegal issues, such as family leave and disability options (FMLA and ADA). Talk with your health care provider about their recommendations for limitations and/or return to work. 	National Institute on Aging (NIH): Choosing a Doctor www.nia.nih.gov/HealthInf ormation/Publications/choos ing.htm www.cancerand careers.org www.eeoc.gov
Potential for Psychosocial Distress and Depression	 Seek professional help if you are having emotional issues Studies have shown that exercise and movement is beneficial for depression and emotional distress. 	CancerCare Online Support http://supportgroups.canc ercare.org/ Telephone Support Groups: CancerCare 1-800-813- 4673 City of Hope Biller Patient and Family Resource Center: 626-256-4673 X32273

Potential for Menopausal Symptoms	 Premenopausal women treated for breast cancer often enter a premature menopause, with resulting loss of childbearing capacity and menopausal symptoms. Keep track of the symptoms you're experiencing. For instance, write down how many hot flashes you experience in a day or a week and how severe they are. This will aid you in your discussions with your health care provider. Cool hot flashes. Get regular exercise, dress in layers and try to pinpoint what triggers your hot flashes. Keep the thermostat low, use portable fans at your desk and bedside, and replace hot beverages with cold ones. Optimize your sleep. Avoid caffeine and plan to exercise during the day. Eat a balanced diet. Heavier women have more hot flashes. Don't smoke (nonsmokers have fewer vasomotor symptoms than do smokers). Get at least 30 minutes of moderate-intensity physical activity on most days. Always talk with your health care provider about any alternative medications you may be considering for menopausal symptoms as they may not be appropriate for women who have been treated for breast cancer. 	Managing Menopausal Symptoms, www.breastcancer.org http://www.breastcancer.org /tips/menopausal/
Potential for Memory and Thinking Problems	 Often called "chemobrain", this side effect of chemotherapy causes some people to have trouble remembering simple things. Try using a detailed daily planner Get enough rest and sleep Regular physical exercise can be beneficial. Set up and follow routines. Try to keep the same daily schedule. Don't try to multi-task. Focus on one thing at a time Track your memory problems. Keep a diary of when you notice problems and the events that are going on at the time. Medicines taken, time of day, and the situation you are in may help you figure out what affects your memory. 	American Cancer Society: Chemo Brain http://www.cancer.org/docr oot/MBC/content/MBC_2_3 x_Chemobrain.asp
Obesity/High Cholesterol	 A healthy weight depends on a person's height, so recommendations for a healthy weight are often expressed in terms of body mass index (BMI). BMI is a measure of body fat based on height and weight. Keep your weight down. Women who are overweight are more likely to get cancers of the colon, esophagus and kidney. Obesity and overweight increase the risk for serious medical conditions: diabetes, fatty liver, gallbladder disease, gastroesophageal reflux (GERD), gout, osteoarthritis, coronary artery disease, hypertension, stroke and sleep apnea. Eat a healthy diet each day: five or more servings of fruit and vegetables high fiber food (whole grain breads, pastas, cereal, rice, etc.) choose fish, turkey, chicken, and beans; limit red meats limit fried food, high sugar foods eat high calcium food (milk products including yogurt, cheese, and dark green vegetables eat low fat foods 	American Cancer Society: Food and Fitness www.cancer.org/docroot/PE D/ped_3.asp?sitearea=PED



Systematic Review of the Impact of Cancer Survivorship Care Plans on Health Outcomes and Health Care Delivery

Paul B. Jacobsen, Antonio P. DeRosa, Tara O. Henderson, Deborah K. Mayer, Chaya S. Moskowitz, Electra D. Paskett, and Julia H. Rowland

- 11 randomized and 13 non-randomized trials address survivorship care plans
- Randomized trials did not show benefit for improving physical, functional, and psychological well-being.

Conclusion

Existing research provides little evidence that SCPs improve health outcomes and health care delivery. Possible explanations include heterogeneity in study designs and the low likelihood that SCP delivery alone would influence distal outcomes. Findings are limited but more positive for proximal outcomes (eg, information received) and for care delivery, particularly when SCPs are accompanied by counseling to prepare survivors for future clinical encounters. Recommendations for future research include focusing to a greater extent on evaluating ways to ensure SCP recommendations are subsequently acted on as part of ongoing care.

- To provide evidence-based data for the addressing the complications of therapy
- Ensure appropriate surveillance for second malignancies
- Address lifestyle issues
- Provide an opportunity to study treatment related effects




Physical and Psychosocial Longterm and Late Effects of Cancer Treatment

- Lymphedema
- Cardiotoxicity
- Infertility
- Bone health
- Pain and neuropathy
- Musculoskeletal health
- Premature menopause

- Body image concerns
- Distress, depression, anxiety
- Fatigue
- Cognitive Impairment
- Health promotion
- Sexual health




Survivorship Website cityofhope.sharepoint.com/teams/Survivorship




🐹 Cityof Hope.


click here to visit the Thriving After Cancer registration website




犹 Cityof Hope.

- Mental Health
- Nutrition and Healthy eating
- Physical Activity and Wellness
- Sexual Health & Fertility
- Sleep
- Complementary Medicine
- Surveillance & Cancer Prevention
- Advance Directive





FOR PATIENTS ON AN AROMATASE INHIBITOR OR ANDROGEN DEPRIVATION THERAPY



犹 Cityof Hope.

Survivorship Work Groups



Sexual Health Work Group



Exercise & Lifestyle Work Group



Financial & Legal Resources Work Group

Prevalence of treatment-related symptoms in patients following (neo)adjuvant endocrine therapy with or without chemotherapy



Women with Stage I-III breast cancers after completion of (neo)adjuvant therapy




Completion of tablet-based Survivorship SupportScreen[®] with 25 biopsychosocial questions



Prevalence of treatment-related symptoms

	CT+ET N=113	ET alone N=91	P- value
Mean age	54.8 years	60.89 years	<0.001
Fatigue	81/110 (73.64%)	65/88 (73.86%)	0.971
Worry about recurrence	77/113 (68.14%)	60/91 (65.93%)	0.739
Sleeping	70/112 (62.5%)	51/91 (56.04%)	0.351
Not being physically active	67/110 (60.9%)	50/89 (56.18%)	0.500
Neuropathy	64/113 (56.64%)	29/91 (31.87%)	<0.001
Pain	62/112 (55.36%)	43/90 (47.78%)	0.284
Hot flashes	61/113 (53.98%)	52/91 (57.14%)	0.652
Thinking clearly	53/111 (47.75%)	38/89 (42.7%)	0.476
Vaginal dryness	47/113 (41.59%)	31/91 (34.07%)	0.271
Gained weight	45/113 (39.82%)	34/91 (37.36%)	0.720





	All (Men and Women)	Men	Women
Overweight or Obesity	70.2	73.7	66.9
Overweight	32.5	38.7	26.5
Obesity (including extreme obesity)	37.7	35	40.4
Extreme obesity	7.7	5.5	9.9

NHANES 2013-2014

Weight gain after breast cancer diagnosis and mortality

Table 2. Comparison of meta-analysis results: fixed vs random effects*

			Fixed effects P† I ² (%)				Random effects	
Comparison	Subgroup	HR (95% CI)			Chi ² P†	HR (95% CI)	P‡	Tau ²
Weight gain >5.0% and all-cause mortality	_	1.12 (1.03 to 1.22)	.01	55.0	.02	1.17 (1.01 to 1.36)	.03	0.03
Weight gain and all-cause mortality,	5–10.0%	0.97 (0.86 to 1.11)	.69	0.0	.98	0.97 (0.86 to 1.11)	.69	0.00
stratified by level of weight gain	>10.0%	1.23 (1.09 to 1.39)	<.001	62.0	.03	1.33 (1.05 to 1.67)	.02	0.04
Weight gain >5.0% and all-cause	BMI < 25	1.14 (0.99 to 1.31)	.07	0.0	.80	1.14 (0.99 to 1.31)	.07	0.00
mortality, stratified by prediagnosis BMI	$BMI \ge 25$	1.00 (0.86 to 1.16)	.96	23.0	.27	1.02 (0.84 to 1.23)	.86	0.01
Weight gain and breast cancer–specific	5-10.0%	0.98 (0.83 to 1.15)	.77	0.0	.99	0.98 (0.83 to 1.15)	.77	0.00
mortality, stratified by level of weight gain	>10.0%	1.17 (1.00 to 1.38)	.05	46.0	.12	1.31 (1.00 to 1.71)	.05	0.04
Weight gain >5.0% and breast cancer recurrence	—	0.93 (0.77 to 1.13)	.46	52.0	.12	0.97 (0.70 to 1.34)	.85	0.04

* - = not applicable; BMI = body mass index; CI = confidence interval; HR = hazard ratio.

† The P values were calculated from Chi² test for heterogeneity. All tests were two-sided (P < .05).

‡ The P values were calculated from Tau² test for heterogeneity. All tests were two-sided (P < .05).

Playdon, JCNI 2015; 107 (12)



Weight gain after breast cancer diagnosis and mortality

- •Wt gain \geq 5% vs < 5% fall cause mortality
- •5-10% weight gain NS
- I 10% weight gain associated with f all cause mortality (HR=1.23) NO increase in cancer-specific mortality




What is the impact of body composition?

Shape shifting



Changes in body composition changes induced by menopause




11βHSD1: 11-beta-hydroxysteroid-dehydrogenase type 1

Pippa, Endocrinology Metabolism Syndrome 2012




Changes in Adipose Tissues with Weight Gain



Picon-Ruiz, CA Cancer J Clin 2017;67:378-397

Metabolic Syndrome and Type 2 Diabetes



Yee, Frontiers in Endocrinology 2020;11:58


犹 Cityof Hope.



Diabetes and worse outcomes

 Meta-analysis of 17 studies with 48,315 women with breast cancer

DFS by diabetes or not



 Diabetes is independently associated with poor overall survival and DFS in female breast cancer patients

Zhao and Ren, Medicine 2016;95:49

Shape shifting in breast cancer patients

Menopause

Chemotherapy castration effects

Endocrine therapy

Tamoxifen
Aromatase inhibitors


- Aging
- Chemotherapy?



Metabolic Syndrome and Chemotherapy

Why should an oncologist care about Metabolic Syndrome?

- Health and well-being
- Higher incidence of cancer
- Disease outcome
- Quality of Life




Does chemotherapy cause Metabolic Syndrome in women without Metabolic Syndrome?

Screened 963 women

Only 157 did not have Metabolic Syndrome

86 Consented



Before Chemo





15 weeks of chemotherapy



After Chemo








Impact of chemotherapy on Metabolic Syndrome in women with curable breast cancer – Changes after only 15 weeks of chemotherapy

- A new diagnosis of Metabolic Syndrome was made in 72%
- Weight increased 12 lbs
- Fat mass increased 19 lbs
- % Fat increased 3%
- Total Cholesterol 16.5
- HbA1c increased 0.9 points



Dieli-Conwright, Cancer 2016; 122:2646-53





What can you do about Metabolic Syndrome?

- Treat elevated blood sugars
- Exercise
- Sleep
- Diet
- Medication



Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial

Christina M. Dieli-Conwright, Kerry S. Courneya, Wendy Demark-Wahnefried, Nathalie Sami, Kyuwan Lee, Thomas A. Buchanan, Darcy V. Spicer, Debu Tripathy, Leslie Bernstein, and Joanne E. Mortimer


- Women undergoing (neo) adjuvant chemotherapy
- Exercise intervention with a supervised moderate-tovigorous—65% to 85% of heart rate maximum—aerobic and resistance exercise three times per week for 16 weeks
- 50 patients in each arm

Impact of aerobic and resistance exercise on MetS

	Intervention	Usual Care
Metabolic Syndrome		
Baseline	39/50 (78%)	38/50 (76%)
Post-Intervention	7/47 (15%)	36/45 (78%)
BMI (mean)		
Baseline	33.5	33.3
Post-Intervention	28	34.4




Mechanism of association between sleep disorders and obesity



Muscogiuri, International J of Obesity Suppl 2020; 10: 62-71



Women's Health Initiative Dietary Modification Trial



Analysis Endpoints: Deaths from breast cancer. Deaths after breast cancer Clinical follow-up plus National Death Index queries


Dietary Intervention: Goal to reduce fat intake to 20% and increase fruit, vegetables, and grain



Participant flow for women who received a breast cancer diagnosis during the dietary intervention period for analysis of breast cancer overall survival

 At a median of 8.5 years there were 8% fewer breast cancers (p=0.09)


 Fewer poor prognosis ER+/PR-/HER2- cases (p=0.04)



Chlebowski, JAMA Oncology, 2018;1212



Dietary Modification associated with breast cancer overall survival Median 11.5 years post breast cancer diagnosis



Conclusion: of those women diagnosed with breast cancer during the intervention period, overall survival was superior in those on the intervention arm.

Chlebowski, JAMA Oncology, 2018;1212







ARTICLE

Clinical Study

Low-fat dietary pattern and breast cancer mortality by metabolic syndrome components: a secondary analysis of the Women's Health Initiative (WHI) randomised trial


Kathy Pan¹, Aaron K. Aragaki², Marian L. Neuhouser², Michael S. Simon^{3,4}, Juhua Luo⁵, Bette Caan⁶, Linda Snetselaar⁷, Joanne E. Mortimer⁸, JoAnn E. Manson⁹, Candyce Kroenke⁶, Dorothy Lane¹⁰, Kerryn Reding¹¹, Thomas E. Rohan¹² and Rowan T. Chlebowski¹

Death from Breast Cancer by Metabolic Syndrome Components

	Intervention N(%)	Comparison N(%)	HR(95%CI)	P		
Overall influence on death from breast cancer	132(0.037)	251(0.047)	0.79(0.64,0.97)	0.02	+	
Waist >=88cm				0.37		
No	60(0.033)	101(0.037)	0.89(0.64,1.22)			
Yes	72(0.042)	150(0.057)	0.73(0.55,0.97)			
Diabetes ever*				0.49		
No	126(0.037)	235(0.046)	0.80(0.65,1.00)			
Yes	6(0.032)	16(0.055)	0.57(0.22,1.48)	-		(
Elevated blood pressure*				0.44		
No	45(0.032)	78(0.037)	0.85(0.59,1.23)			
Yes	78(0.040)	164(0.056)	0.71(0.54,0.93)		_	
High cholesterol requiring pills†				0.20		
No	119(0.037)	214(0.045)	0.83(0.66,1.03)			
Yes	13(0.033)	37(0.062)	0.53(0.28,1.01)	1		
Metabolic syndrome score‡				0.01		
None	23(0.028)	31(0.026)	1.09(0.63,1.87)	_		
1-2 abnormalities	93(0.041)	176(0.052)	0.80(0.62,1.02)			
3-4 abnormalities	7(0.026)	35(0.081)	0.31(0.14,0.69)			
				0.25	0.50 0.75 1.00 1.33 2.00 4.00 HR(95%CI)	0

Favors intervention :

GLP-1 actions



犹 Cityof Hope.

The NEW ENGLAND JOURNAL of MEDICINE


ESTABLISHED IN 1812 MA

MARCH 18, 2021

VOL. 384 NO. 11

Once-Weekly Semaglutide in Adults with Overweight or Obesity

 John P.H. Wilding, D.M., Rachel L. Batterham, M.B., B.S., Ph.D., Salvatore Calanna, Ph.D., Melanie Davies, M.D., Luc F. Van Gaal, M.D., Ph.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Barbara M. McGowan, M.D., Ph.D.,
 Julio Rosenstock, M.D., Marie T.D. Tran, M.D., Ph.D., Thomas A. Wadden, Ph.D., Sean Wharton, M.D., Pharm.D.,
 Koutaro Yokote, M.D., Ph.D., Niels Zeuthen, M.Sc., and Robert F. Kushner, M.D., for the STEP 1 Study Group*









THANK YOU!

